ATLANTA, GA – – (Globe Newswire – March 9, 2026) – – A shareholder class action lawsuit has been filed against Nektar Therapeutics (“Nektar”) (NASDAQ: NKTR). The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts, including allegations that: (i) enrollment in Nektar’s REZOLVE-AA trial had not followed applicable instructions and protocol standards; (ii) the foregoing was likely to have a significant negative impact on the REZOLVE-AA trial’s results; and (iii) accordingly, the REZOLVE-AA trial’s overall integrity and prospects were overstated.

If you purchased Nektar’s shares between February 26, 2025 and December 15, 2025, and experienced a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832, or by visiting the firm’s website at www.holzerlaw.com/case/nektar-therapeutics/ for more information.

The deadline to ask the court to be appointed lead plaintiff in the case is May 5, 2026.